Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02419560
Title Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Craig Portell, MD
Indications

mantle cell lymphoma

Therapies

Ibrutinib + Venetoclax

Age Groups: adult
Covered Countries USA


No variant requirements are available.